Published in J Pharmacol Toxicol Methods on July 25, 2005
Principles of safety pharmacology. Br J Pharmacol (2008) 1.27
Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data. J Comput Aided Mol Des (2007) 1.12
Induced pluripotent stem cells as a disease modeling and drug screening platform. J Cardiovasc Pharmacol (2012) 1.09
Small and large animal models in cardiac contraction research: advantages and disadvantages. Pharmacol Ther (2013) 1.08
Ibandronate and ventricular arrhythmia risk. J Cardiovasc Electrophysiol (2013) 1.01
Scorpion toxins specific for potassium (K+) channels: a historical overview of peptide bioengineering. Toxins (Basel) (2012) 0.91
Identification of Ikr kinetics and drug binding in native myocytes. Ann Biomed Eng (2009) 0.84
Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts. Br J Pharmacol (2006) 0.83
The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys. Br J Pharmacol (2008) 0.80
hERGAPDbase: a database documenting hERG channel inhibitory potentials and APD-prolongation activities of chemical compounds. Database (Oxford) (2011) 0.80
The virtual heart as a platform for screening drug cardiotoxicity. Br J Pharmacol (2015) 0.77
Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res (2004) 1.07
Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res (2003) 0.96
Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors. J Med Chem (2015) 0.79
Respiratory function in rats restrained for extended periods: assessment of the effects of bethanecol. J Pharmacol Toxicol Methods (2005) 0.79
Benchmarking safety pharmacology regulatory packages and best practice. J Pharmacol Toxicol Methods (2008) 0.79
Psychoanalytic supervision of the difficult patient. Psychoanal Q (2003) 0.75